Core Insights - GSK emphasizes its commitment to health management through a combination of prevention and treatment, showcasing its innovative product pipeline at the 2025 China International Import Expo [1][3][6] Group 1: Innovation and Product Pipeline - GSK presented several innovative products, including the world's first approved RSV vaccine and a drug for chronic hepatitis B that aims for "functional cure" [1][3] - The company also introduced a long-acting monoclonal antibody for chronic diseases and a first-in-class antibody-drug conjugate for multiple myeloma, covering various therapeutic areas [1][3] Group 2: Health Management Strategy - GSK is focused on integrating prevention and treatment, aiming to create a comprehensive health management model that spans the entire lifecycle of diseases [3][4] - The company has a long history in hepatitis management, providing innovative solutions from vaccines to antiviral treatments [3] Group 3: Collaboration and Market Strategy - GSK has established partnerships with local companies to enhance the accessibility of its vaccines and support healthcare initiatives in China [5] - The company plans to accelerate its local market strategy, with over 80% of its R&D projects in China aligned with global development, aiming to introduce approximately 18 new products and indications in the next three years [6]

Core Insights - GSK showcased its commitment to health management at the 8th China International Import Expo with the theme "Collaborate to Surpass, Create a Healthy Future" [1] - The company emphasizes a shift from disease-centered to health-centered pharmaceutical innovation, aligning with China's "Healthy China" initiative [1][2] - GSK presented several innovative products, including the world's first approved RSV vaccine and a drug for functional cure of chronic hepatitis B [1][2] Group 1: Product Innovations - GSK introduced a range of innovative pipeline products, including the first RSV vaccine approved globally and a long-acting drug for chronic hepatitis B [1] - The company also highlighted the first antibody-drug conjugate for multiple myeloma and a long-acting treatment for HIV [3] - GSK's new shingles vaccine is the first approved for adults with immunodeficiency due to known diseases or treatments [2] Group 2: Strategic Collaborations - GSK is collaborating with Hengrui Medicine to develop up to 12 innovative drugs across various therapeutic areas [3] - The company aims to deepen its local market presence with a strategy focused on speed, direction, and priority [3] - Over 80% of GSK's R&D projects in China are now integrated into global development, with approximately 18 new products expected to be approved in the next three years [3]

Group 1: Event Overview - The 8th China International Import Expo (CIIE) is held from November 5 to 10 at the National Exhibition and Convention Center in Shanghai [1] - The event showcases 461 new products, technologies, and services, transforming into a global stage for innovation [2] Group 2: Medical and Health Innovations - The medical device and healthcare exhibition area features significant innovations, including Siemens Healthineers' brain-machine interface solution, which integrates advanced imaging and navigation technologies [3] - Sanofi's innovative drug, Tregalizumab, for delaying the progression of Type 1 diabetes, has been approved in China after its debut at the expo [4] - Abbott presents over ten innovative products, including a dynamic blood glucose monitoring system that meets international standards [5] Group 3: Pharmaceutical Developments - GSK introduces several groundbreaking products, including the first approved RSV vaccine and a long-acting treatment for chronic hepatitis B [6] - EssilorLuxottica showcases new products for myopia management and wearable devices, emphasizing innovation in vision health [7] Group 4: Life Sciences and Technology - Illumina presents new solutions for protein detection and gene sequencing, highlighting advancements in life sciences [8][9] - The company emphasizes local manufacturing and partnerships to enhance its technological capabilities in China [8] Group 5: Consumer Goods and Sustainability - LEGO Group unveils five globally launched products inspired by Chinese culture, focusing on sustainability and creativity [10][11] - Kao's freeplus brand showcases its research in amino acid-based skincare, aiming to deepen its market presence in China [11] Group 6: Market Strategies and New Products - Skechers uses the expo as a strategic platform for launching new sports products, reinforcing its commitment to the Chinese market [12][13] - Ausnutria presents 61 products across various nutritional categories, emphasizing innovation and market responsiveness [14]

北京商报讯（记者 王寅浩 宋雨盈）11月6日，第八届中国国际进口博览会（以下简称"进博会"）葛兰素 史克（以下简称"GSK"）展台正式揭幕，今年GSK以"合力超越，创健未来"为主题，展台呈现了其在防 治结合、全生命周期健康管理方面的布局和理念。据悉，这已经是GSK连续八年参展进博会。 本届进博会上，GSK带来了多款创新管线产品。其中包括全球首款获批上市、在中国首个开展三期临床 的呼吸道合胞病毒（RSV）疫苗，全球首个有望实现慢性乙型肝炎"功能性治愈"的反义寡核苷酸 （ASO）类药物，可实现六个月一次长效给药的德莫奇单抗，以及针对多发性骨髓瘤的全球首个抗 BCMA抗体偶联药物注射用玛贝兰妥单抗，覆盖呼吸、免疫与炎症，感染性疾病，肿瘤等多个治疗领 域。 此外，曾在进博会展出过的重组带状疱疹疫苗欣安立适、新可来（美泊利珠单抗）此次也将携新适应症 再度亮相本届进博会。 GSK近年来积极拓展本土合作，与智飞生物推进带状疱疹疫苗可及性，今年，更与恒瑞医药达成合作， 将共同开发至多12款涵盖呼吸、自免和炎症、肿瘤治疗领域的创新药物。 目前，GSK超过80%的中国研发项目已并入全球同步开发，同时，始终聚焦于慢性乙肝等中国高发 ...

第八届中国国际进口博览会如约而至，葛兰素史克（GSK）作为连续八届参展的"老朋友"，在呼吸领域 持续加速研发，今年更是携旗下完整的呼吸产品管线从预防到治疗，从吸入式制剂到生物制剂再次参 展，交出一份亮眼的GSK呼吸革新答卷。 "这三年，我见证了GSK呼吸业务的变革。"GSK副总裁、中国呼吸业务负责人余锦毅在接受经济观察报 记者专访时如此开场。 三年前余锦毅加入GSK时，公司呼吸产品线还以吸入制剂为主；三年后，GSK已经构建了从预防到治疗 再到全程管理的完整呼吸健康生态系统。这场变革不仅仅体现在产品线的丰富，更是治疗理念、服务模 式和产业生态的全面升级。 这场全面升级的背后，是GSK变革的最佳印证，更是中国医药行业黄金三年的时代缩影。带量采购常态 化、创新药审评审批加速、医保目录动态调整等一系列政策重塑着行业格局。据统计，近三年来中国创 新药审评审批速度提升显著，2024年创新药获批数量是2018年的5倍以上1。与此同时，国家医保谈判通 过双"通道"等机制大幅提升创新药可及性，惠及更多患者。 作为全球呼吸领域领导者，GSK在这片变革的土壤中深耕的路径选择，颇具启示意义。从吸入制剂到生 物制剂，从单一产品到全程管 ...